Medtronic touts AdaptivCRT data on atrial fibrillation September 23, 2013 By Brad Perriello Leave a Comment Medtronic (NYSE:MDT) touted a clinical trial it said showed a 46% reduction in atrial fibrillation among patients using the Vivo line of cardiac resynchronization therapy-defibrillators featuring its AdaptivCRT feature.